WO2002089768A1 - Liquid injectable formulation of disodium pamidronate - Google Patents

Liquid injectable formulation of disodium pamidronate Download PDF

Info

Publication number
WO2002089768A1
WO2002089768A1 PCT/CA2001/001617 CA0101617W WO02089768A1 WO 2002089768 A1 WO2002089768 A1 WO 2002089768A1 CA 0101617 W CA0101617 W CA 0101617W WO 02089768 A1 WO02089768 A1 WO 02089768A1
Authority
WO
WIPO (PCT)
Prior art keywords
solution
process according
group
pamidronate
physiologically acceptable
Prior art date
Application number
PCT/CA2001/001617
Other languages
French (fr)
Inventor
Sam Hahn
Dennis Szymanski
Original Assignee
Pharmaceutical Partners Of Canada Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4169021&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2002089768(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmaceutical Partners Of Canada Inc. filed Critical Pharmaceutical Partners Of Canada Inc.
Publication of WO2002089768A1 publication Critical patent/WO2002089768A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Definitions

  • the present invention relates to an improved injectable ready to use preparation of pamidronate salts of the formula given by
  • 3-amino-l-hydroxypropane-l,l-diphosphonate disodium, the disodium salt of pamidronic acid is a well-known compound useful as a bone resorption inhibitor.
  • pamidronate pamidronate disodium or disodium pamidronate
  • the compound is part of the therapeutic class of compounds called bisphosphonates.
  • Bisphosphonates used as inhibitors of bone resorption all contain two phosphonate groups attached to a single carbon atom, forming a "P- C-P" structure.
  • the bisphosphonates are therefore stable analogues of naturally occurring pyrophosphate-containing compounds, which now helps to explain their intracellular as well as their extracellular modes of action.
  • bisphosphonates inhibit bone resorption by being selectively taken up and adsorbing to mineral surfaces in bone, where they interfere with the action of osteoclasts. It is likely that bisphosphonates are internalized by osteoclasts and interfere with specific biochemical processes and induce apoptosis.
  • bisphosphonates including etidronate, clodronate, pamidronate, alendronate, and risedronate are established as effective treatments in clinical disorders such as Paget's disease of bone, hypercalceamia of a malignancy, and bone metastases. Bisphosphonates are also now well established as successful antiresorptive agents for the prevention and treatment of osteoporosis. Additional indications include the reduction of bone pain associated with certain illnesses and to treat bone loss due to breast cancer.
  • U.S. Patents 4,71 1,880 and 4,639,338 to Stahl et al. disclose the preparation of the crystalline pentahydrate form of disodium pamidronate from pamidronic acid.
  • a heated aqueous suspension of pamidronic acid is partially neutralized with aqueous sodium hydroxide (NaOH) to pH 7 to 7.5. Crystallization is then initiated and the disodium pamidronate is collected by filtration.
  • the pentahydrate comprises about 24.1 to 25% water and the product is stable to storage under approximately normal ambient conditions.
  • the commercially available formulation, AREDIATM contains the lyophilized form of pamidronate disodium pentahydrate
  • disodium pamidronate converts to the pentahydrate depending upon humidity and amount of water present (Stahl et al.) resulting in varying compositions of hydrates. Accordingly, it is difficult to use preformed disodium salts of pamidronic acid (such as anhydrous or partially hydrated forms other than pentahydrate) for further processing into sterile pharmaceuticals due to the interconversion of other crystalline forms of disodium pamidronate.
  • pamidronic acid such as anhydrous or partially hydrated forms other than pentahydrate
  • pamidronate is usually administered intravenously, due to the poor absorption from the gastrointestinal system.
  • Pamidronate is supplied commercially as a lyophilized powder that must be reconstituted with a pharmaceutically acceptable solvent before administration to a patient.
  • a lyophilized formulation problems associated with a lyophilized formulation include a risk of microbial contamination during reconstitution and an inability to terminally sterilize the drug product. Double handling of the drug is required, as the lyophilized drug is first required to be reconstituted and then administered. Additionally, time is needed to dissolve the powder and prolonged shaking may be required.
  • Pamidronate in a liquid formulation has been shown to be unstable/reactive during long-term storage (Canadian patent application 2,141 ,964). In addition, current guidelines for storage of reconstituted solutions state that the solution should not be kept for more than 24 hours.
  • Another liquid formulation of disodium pamidronate is disclosed in U.S. 6,160,165 to Shinal.
  • This formulation is prepared by making a stirred slurry of pamidronic acid in water (pamidronic acid is not soluble in water); adding an aqueous solution of sodium hydroxide to the slurry in an about 2:1 molar ratio of sodium hydroxide to pamidronic acid to yield a solution having visual clarity.
  • the solution is packaged in a sealed container to yield a liquid dosage form of pamidronate. No data is given on its stability. No information is provided on sterilization of the solution to yield a pharmaceutically acceptable product.
  • the patent further discloses a lyophilized form of pamidronate, made by the steps above, filtering the solution and freezing and lyophilizing the filtered solution to yield amorphous, essentially anhydrous disodium pamidronate.
  • This process has the disadvantage of a number of manufacturing steps. Additionally, the liquid composition cannot be stored for long periods of time as reaction of the pamidronate with polyvalent cations will occur when stored in glass vials.
  • the pharmaceutically acceptable water soluble alkaline salt is the disodium salt.
  • an injectable, sterile, ready to use, pyrogen-free pamidronate solution comprising a physiologically acceptable water soluble alkaline salt and a physiologically acceptable aqueous solvent having a concentration of between 0.1 and 100 mg/mL which has not been reconstituted from a lyophilizate wherein the solution is provided in a sealed non-reactive container.
  • a prbcess for producing a sterile, injectable, pyrogen-free, ready-to-use pamidronate solution comprising (1) adding pamidronic acid to an aqueous solvent wherein the aqueous solvent contains sodium hydroxide, potassium hydroxide, or water soluble organic amines and (2) sterilizing the solution.
  • sodium hydroxide is mixed with pamidronic acid in a 2 to 1 molar ratio in an aqueous solvent to make pamidronate disodium.
  • the solution is stored in plastic vials, with non-reactive stoppers such as TeflonTM coated/faced stoppers.
  • the invention provides for use of the solution to treat diseases selected from the group of tumour-induced hypercalcemia, Paget's disease, osteoporosis, bone metastases, and breast cancer.
  • Any physiologically acceptable alkaline salt that is water-soluble may be used for preparing the solution of the invention.
  • Preferred salts are sodium and potassium.
  • the disodium salt is the most preferred salt.
  • aqueous sodium hydroxide is added to a non-reactive mixing tank such as a polypropylene tank.
  • Pamidronic acid is mixed with sodium hydroxide, in a 1 :2 molar ratio, in an aqueous environment.
  • Any aqueous solvent that is physiologically acceptable in which pamidronate remains soluble may be used.
  • the solution of the invention may also contain one or more additional components such as a preservative, a co-solublizing agent, or any other desired agent. Suitable solvents include those that have acceptable paniculate counts, such as water, or physiological saline.
  • Tonicity adjustment agents in an amount that does not cause precipitation may be added, such as sodium chloride, dextrose,,lactose, mannitol and the like.
  • preservatives suitable for a physiological administration such as hydroxybenzoic acid esters, chlorobutanol and benzyl alcohol may be added.
  • pH adjustment is not necessary for stability purposes, optionally, the pH may be adjusted within the range of from 6 to 10 using any known method of pH adjustment.
  • the concentration of the solution may be anywhere from 0.1 mg/mL to
  • Non-reactive when used herein means that the packaging material must not contain multivalent metal cations that can react with the pamidronate entity.
  • the preferred packaging material is plastic such as polypropylene, polyolefin, cycloolefin, polycarbonate, ABS resin, polyethylene, or PVC.
  • the containers are vials with non-reactive stoppers.
  • Preferred stoppers are TeflonTM coated/faced. Silicone rubber stoppers or other non- reactive stoppers are contemplated.
  • non-reactive intravenous bags and non-reactive ampoules, such as zirconium ampoules or form seal ampoules.
  • Sterility of the product may be assured through making the product in aseptic conditions, or other methods for sterilization may be used.
  • An advantage of the present invention is the ability to use terminal sterilization processes such as autoclavmg.
  • Terminal sterilization when used herein, means steam sterilization by autoclaving using a using a process validated to deliver a minimum end of exposure Fo of 8 minutes and a maximum Fo of 15 minutes.
  • the solution may be autoclaved according to methods known in the art. Alternatively, the solution may be passed through a sterilizing filter, such as a 0.22 micron Supor DCF capsule.
  • solutions of the invention are characterized by good stability. Solutions have been found to be stable for long periods at room temperature. This is illustrated in the examples which follow.
  • compositions of the present invention are useful for treating any bone resorption disorders or conditions. Examples of these indications are tumor-induced hypercalcemia, conditions associated with increased osteoclast activity, predominantly lytic bone metastases and multiple myeloma as well as symptomatic Paget's disease of bone.
  • the composition of the present invention is designed to be diluted and administered as a slow intravenous infusion.
  • the injectable solutions of the invention are administered according to a variety of possible dose schedules. Suitable dose schedules are for example 90 mg as a 2 hour infusion in 250 ml infusion solution or a maximum of 90 mg in 500 ml over 4 hours for patients with multiple myeloma or tumor induced hypercalcemia.
  • the total dose for a treatment course may be given as a single infusion, or in multiple infusions spread over 2-4 consecutive days.
  • the maximum dose should be 90 mg.
  • the recommended total dose of pamidronate disodium injection for a treatment _ course for Paget's disease of the bone is 180-210 mg either administered as 6 doses of 30 mg once a week or 3 doses of 60 mg every second week following initiation with a 30 mg dose.
  • Water for injection USP was collected in a clean, non-reacting polypropylene mixing tank at room temperature. Sodium hydroxide NF was added to the water and mixed thoroughly until completely dissolved. Pamidronic acid was then added and mixed until completely dissolved. Mannitol USP was then added and completely dissolved. The pH was then adjusted to between 6.4 and 6.6 with 10% phosphoric acid. Water for injection USP was added to the final required volume.
  • the solution was filtered through a sterilizing 0.22 micron Supor-DCF filter. Volumes of 10 ml of the solution were distributed into plastic vials. The vials were then closed with TeflonTM-faced coated rubber stoppers and sealed, and steam sterilized by autoclaving using a using a process validated to deliver a minimum end of exposure Fo of 8 minutes and a maximum Fo of 15 minutes.

Abstract

The present invention relates to an improved injectable ready to use preparation of pamidronate salts, methods for its manufacture and uses of the solution of the invention in the manufacture of pharmaceutical compositions for the treatment of diseases selected from the group of tumour-induced hypercalcaemia, Paget's disease, osteoporosis, bone metastases, or breast cancer. The ready to use solution comprises a physiologically acceptable alkaline salt which is water soluble and a physiologically acceptable aqueous solvent having a concentration of between 0.1 and 100 mg/mL which has not been reconstituted from a lyophilizate, wherein the solution is provided in a sealed non-reactive container.

Description

LIQUID INJΕCTABLE FORMULATION OF DISODIUM PAMIDRONATE
Field of the Invention
The present invention relates to an improved injectable ready to use preparation of pamidronate salts of the formula given by
I OsHNa
Figure imgf000002_0001
POsH a
Background of the Invention
3-amino-l-hydroxypropane-l,l-diphosphonate disodium, the disodium salt of pamidronic acid, is a well-known compound useful as a bone resorption inhibitor. Also known as pamidronate, pamidronate disodium or disodium pamidronate, the compound is part of the therapeutic class of compounds called bisphosphonates. Bisphosphonates used as inhibitors of bone resorption all contain two phosphonate groups attached to a single carbon atom, forming a "P- C-P" structure. The bisphosphonates are therefore stable analogues of naturally occurring pyrophosphate-containing compounds, which now helps to explain their intracellular as well as their extracellular modes of action. The mode of action of bisphosphonates was originally ascribed to physico-chemical effects on hydroxyapatite crystals, a major inorganic component of bone, but it has gradually become clear that cellular effects must also be involved. Bisphosphonates inhibit bone resorption by being selectively taken up and adsorbing to mineral surfaces in bone, where they interfere with the action of osteoclasts. It is likely that bisphosphonates are internalized by osteoclasts and interfere with specific biochemical processes and induce apoptosis.
Several bisphosphonates including etidronate, clodronate, pamidronate, alendronate, and risedronate are established as effective treatments in clinical disorders such as Paget's disease of bone, hypercalceamia of a malignancy, and bone metastases. Bisphosphonates are also now well established as successful antiresorptive agents for the prevention and treatment of osteoporosis. Additional indications include the reduction of bone pain associated with certain illnesses and to treat bone loss due to breast cancer.
U.S. Patents 4,71 1,880 and 4,639,338 to Stahl et al. disclose the preparation of the crystalline pentahydrate form of disodium pamidronate from pamidronic acid. A heated aqueous suspension of pamidronic acid is partially neutralized with aqueous sodium hydroxide (NaOH) to pH 7 to 7.5. Crystallization is then initiated and the disodium pamidronate is collected by filtration. The pentahydrate comprises about 24.1 to 25% water and the product is stable to storage under approximately normal ambient conditions. The commercially available formulation, AREDIA™, contains the lyophilized form of pamidronate disodium pentahydrate
Other crystalline forms of disodium pamidronate convert to the pentahydrate depending upon humidity and amount of water present (Stahl et al.) resulting in varying compositions of hydrates. Accordingly, it is difficult to use preformed disodium salts of pamidronic acid (such as anhydrous or partially hydrated forms other than pentahydrate) for further processing into sterile pharmaceuticals due to the interconversion of other crystalline forms of disodium pamidronate.
At present, pamidronate is usually administered intravenously, due to the poor absorption from the gastrointestinal system. Pamidronate is supplied commercially as a lyophilized powder that must be reconstituted with a pharmaceutically acceptable solvent before administration to a patient.
Problems associated with a lyophilized formulation include a risk of microbial contamination during reconstitution and an inability to terminally sterilize the drug product. Double handling of the drug is required, as the lyophilized drug is first required to be reconstituted and then administered. Additionally, time is needed to dissolve the powder and prolonged shaking may be required. Pamidronate in a liquid formulation has been shown to be unstable/reactive during long-term storage (Canadian patent application 2,141 ,964). In addition, current guidelines for storage of reconstituted solutions state that the solution should not be kept for more than 24 hours.
One answer to the stability problem is proposed in Canadian patent application 2,141 ,964, which discloses injection solutions that are stable when stored in glass packaging, where the pH of the injection and solution is about 3.0 to 4.5 and polyethylene glycols are used to stabilize the solution. However, this formulation contains ingredients that are unnecessary for therapeutic purposes, and the process to prepare the formulation requires several steps, such as pH adjustment.
Another liquid formulation of disodium pamidronate is disclosed in U.S. 6,160,165 to Shinal. This formulation is prepared by making a stirred slurry of pamidronic acid in water (pamidronic acid is not soluble in water); adding an aqueous solution of sodium hydroxide to the slurry in an about 2:1 molar ratio of sodium hydroxide to pamidronic acid to yield a solution having visual clarity. The solution is packaged in a sealed container to yield a liquid dosage form of pamidronate. No data is given on its stability. No information is provided on sterilization of the solution to yield a pharmaceutically acceptable product. The patent further discloses a lyophilized form of pamidronate, made by the steps above, filtering the solution and freezing and lyophilizing the filtered solution to yield amorphous, essentially anhydrous disodium pamidronate. This process has the disadvantage of a number of manufacturing steps. Additionally, the liquid composition cannot be stored for long periods of time as reaction of the pamidronate with polyvalent cations will occur when stored in glass vials.
Assuring sterility of the injection solution is always a concern for a manufacturer. Reconstitution introduces the risk of microbial contamination.
Although the preferred approach to assurance of sterility of a solution, or the gold standard, is terminal steam sterilization through autoclaving, sterile filtration is used when the compound or formulation is subject to lyophilization or is heat sensitive. (Drugs Directorate Guideline, Chemistry and Manufacturing: New Drugs 1990, Health and Welfare Canada).
Ready-to-use solutions of disodium pamidronate, provided in a sealed container, have not been commonly available. Accordingly, there is a need for a stable, ready to use liquid injectable formulation that can be stored at room temperature and does not require reconstitution. There is a need for a solution that can be terminally sterilized. There is also a need for a simplified process for making a stable liquid formulation of disodium pamidronate that does not require pH adjustment nor any expensive freeze drying step.
Summary of the Invention
It is an object of the present invention to provide a storage stable, ready to use solution containing a pharmaceutically acceptable water-soluble alkaline salt of pamidronate as well as a process for its manufacture. In a preferred embodiment, the pharmaceutically acceptable water soluble alkaline salt is the disodium salt.
According to an aspect of the invention, there is provided an injectable, sterile, ready to use, pyrogen-free pamidronate solution comprising a physiologically acceptable water soluble alkaline salt and a physiologically acceptable aqueous solvent having a concentration of between 0.1 and 100 mg/mL which has not been reconstituted from a lyophilizate wherein the solution is provided in a sealed non-reactive container.
According to an aspect of the present invention, there is provided a prbcess for producing a sterile, injectable, pyrogen-free, ready-to-use pamidronate solution comprising (1) adding pamidronic acid to an aqueous solvent wherein the aqueous solvent contains sodium hydroxide, potassium hydroxide, or water soluble organic amines and (2) sterilizing the solution.
Preferably, sodium hydroxide is mixed with pamidronic acid in a 2 to 1 molar ratio in an aqueous solvent to make pamidronate disodium. In a preferred embodiment, the solution is stored in plastic vials, with non-reactive stoppers such as Teflon™ coated/faced stoppers.
The invention provides for use of the solution to treat diseases selected from the group of tumour-induced hypercalcemia, Paget's disease, osteoporosis, bone metastases, and breast cancer.
Detailed Description of the Invention
Any physiologically acceptable alkaline salt that is water-soluble may be used for preparing the solution of the invention. Preferred salts are sodium and potassium. The disodium salt is the most preferred salt.
In a preferred embodiment, aqueous sodium hydroxide is added to a non-reactive mixing tank such as a polypropylene tank. Pamidronic acid is mixed with sodium hydroxide, in a 1 :2 molar ratio, in an aqueous environment. Any aqueous solvent that is physiologically acceptable in which pamidronate remains soluble may be used. The solution of the invention may also contain one or more additional components such as a preservative, a co-solublizing agent, or any other desired agent. Suitable solvents include those that have acceptable paniculate counts, such as water, or physiological saline. Tonicity adjustment agents in an amount that does not cause precipitation may be added, such as sodium chloride, dextrose,,lactose, mannitol and the like.
Optionally, preservatives suitable for a physiological administration such as hydroxybenzoic acid esters, chlorobutanol and benzyl alcohol may be added. Although pH adjustment is not necessary for stability purposes, optionally, the pH may be adjusted within the range of from 6 to 10 using any known method of pH adjustment.
The concentration of the solution may be anywhere from 0.1 mg/mL to
100 mg/mL, preferably from 1 to 25 mg/mL and most preferably between 3 to 9 mg mL. The resulting solution may be filtered to remove particulate matter, and then is filled into non-reactive packaging. "Non-reactive", when used herein means that the packaging material must not contain multivalent metal cations that can react with the pamidronate entity. The preferred packaging material is plastic such as polypropylene, polyolefin, cycloolefin, polycarbonate, ABS resin, polyethylene, or PVC.
Preferably the containers are vials with non-reactive stoppers. Preferred stoppers are Teflon™ coated/faced. Silicone rubber stoppers or other non- reactive stoppers are contemplated. Also within the scope of the present invention is the use of non-reactive intravenous bags, and non-reactive ampoules, such as zirconium ampoules or form seal ampoules.
Sterility of the product may be assured through making the product in aseptic conditions, or other methods for sterilization may be used. An advantage of the present invention is the ability to use terminal sterilization processes such as autoclavmg. "Terminal sterilization", when used herein, means steam sterilization by autoclaving using a using a process validated to deliver a minimum end of exposure Fo of 8 minutes and a maximum Fo of 15 minutes. The solution may be autoclaved according to methods known in the art. Alternatively, the solution may be passed through a sterilizing filter, such as a 0.22 micron Supor DCF capsule.
The solutions of the invention are characterized by good stability. Solutions have been found to be stable for long periods at room temperature. This is illustrated in the examples which follow.
The pharmaceutical compositions of the present invention are useful for treating any bone resorption disorders or conditions. Examples of these indications are tumor-induced hypercalcemia, conditions associated with increased osteoclast activity, predominantly lytic bone metastases and multiple myeloma as well as symptomatic Paget's disease of bone. The composition of the present invention is designed to be diluted and administered as a slow intravenous infusion. The injectable solutions of the invention are administered according to a variety of possible dose schedules. Suitable dose schedules are for example 90 mg as a 2 hour infusion in 250 ml infusion solution or a maximum of 90 mg in 500 ml over 4 hours for patients with multiple myeloma or tumor induced hypercalcemia. The total dose for a treatment course may be given as a single infusion, or in multiple infusions spread over 2-4 consecutive days. The maximum dose should be 90 mg. The recommended total dose of pamidronate disodium injection for a treatment _ course for Paget's disease of the bone is 180-210 mg either administered as 6 doses of 30 mg once a week or 3 doses of 60 mg every second week following initiation with a 30 mg dose.
In light of the present disclosure, those skilled in the art will readily appreciate other methods and applications of the methods of the present invention.
The examples below are non-limiting and are merely representative of various aspects and features of the present invention.
With reference to the examples, the stability testing on the injectable solution was carried out by means of high performance liquid chromatography (HPLC) at the following experimental conditions:
Figure imgf000009_0001
Example 1: Pamidronate disodium solution 9mg mL
Figure imgf000009_0002
Water for injection USP was collected in a clean, non-reacting polypropylene mixing tank at room temperature. Sodium hydroxide NF was added to the water and mixed thoroughly until completely dissolved. Pamidronic acid was then added and mixed until completely dissolved. Mannitol USP was then added and completely dissolved. The pH was then adjusted to between 6.4 and 6.6 with 10% phosphoric acid. Water for injection USP was added to the final required volume.
The solution was filtered through a sterilizing 0.22 micron Supor-DCF filter. Volumes of 10 ml of the solution were distributed into plastic vials. The vials were then closed with Teflon™-faced coated rubber stoppers and sealed, and steam sterilized by autoclaving using a using a process validated to deliver a minimum end of exposure Fo of 8 minutes and a maximum Fo of 15 minutes.
The stability of the solutions in the vials was tested after accelerated testing at 40° C (accelerated stability controls) and at room temperature for a minimum of 6 months. The stability data obtained, using HPLC for the determination of potency are reported in the following Tables 1 and 2.
Figure imgf000011_0001
Figure imgf000012_0001
While the present invention has been described with reference to what are presently considered to be the preferred examples, it is to be understood that the invention is not limited to the disclosed examples. To the contrary, the invention is intended to cover various modifications and equivalent arrangements included within the spirit and scope of the appended claims.

Claims

The embodiments of the invention in which an exclusive privilege or property is claimed are defined as follows:
1. An injectable, sterile, ready to use, pyrogen-free pamidronate solution comprising a physiologically acceptable alkaline salt which is water soluble and a physiologically acceptable aqueous solvent having a concentration of between 0.1 and 100 mg/mL which has not been reconstituted from a lyophilizate, wherein the solution is provided in a sealed non-reactive container.
2. A solution according to claim 1, wherein the physiologically acceptable alkaline salt is selected from the group of sodium and potassium salts.
3. A solution according to claim 1, wherein the physiologically acceptable alkaline salt is the disodium salt.
4. A solution according to any one of .claims 1 to 3, wherein the concentration is between 3 and 9 mg/mL.
5. A solution according to any one of claims 1 to 4, wherein the sealed container is made of a material selected from the group of polypropylene, polyolefin, cycloolefm, polycarbonate, ABS resin, polyethylene, and PVC.
6. A solution according to claim 5, wherein the sealed container additionally comprises a non-reactive stopper.
7. A solution according to claim 6, wherein the stopper is Teflon™-coated/faced.
8. A solution according to any one of claims 1 to 7 which also contains one or more additional components selected from a co-solubilizing agent, a preservative and a tonicity adjustment agent.
9. A solution according to any one of claims 1 to 8 which also contains dextrose, lactose or mannitol as a tonicity adjustment agent.
10. A solution according to any one of claims 1 to 9 having a pH of from 6.3 to 6.7.
11. A solution according to any one of claims 1 to 10 where the solvent is selected from the group consisting of water, and physiological saline.
12. A process for producing a sterile, injectable, pyrogen-free, ready-to-use pamidronate solution comprising: (i) adding pamidronic acid to an aqueous solvent wherein the aqueous solvent is selected from the group of sodium hydroxide, potassium hydroxide and a water soluble organic amine; and (ii) sterilizing the solution.
13. A process according to claim 12, wherein the aqueous solvent is sodium hydroxide.
14. A process according to claim 13, where the molar ratio of sodium hydroxide to pamidronic acid is 2:1.
15. A process according to claim 14 which further comprises placing the solution in a sealed non-reactive container.
16. A process according to claim 15, wherein the sealed container is a plastic vial.
17. A process according to claim 16, wherein the sealed container additionally comprises a non-reactive stopper.
18. A process according to claim 17, wherein the stopper is Teflon™-coateα7faced.
19. A process according to claim 15, wherein the sealed container is selected from the group of a form seal ampoule and plastic bag used for preparation or administration of intravenous solution.
20. A process according to any one of claims 12 to 19 which additionally comprises the step of adjusting the pH of the solution to 6 tolO.
21.. A process according to claim 20 wherein the pH of the solution is adjusted to 6.3 to 6.7.
22. A process according to any one of claims 12 to 20 which comprises the additional step of adding a component selected from the group of co-solubilizing agents, preservatives and tonicity adjustment agents.
23. A process according to claim 12, which comprises the additional step of adding a physiologically acceptable solvent.
24. A process according to any one of claims 12 to 22 wherein the step of sterilization comprises passing the solution through a sterilizing filter.
25. A process according to any one of claims 12 to 23 wherein the step of sterilization comprises terminal sterilization of the sealed containers.
26. The solution made by the process of any one of claims 12 to 25.
27. Use of the solution of any one of claims 1 to 11 for the manufacture of a pharmaceutical composition for the treatment of diseases selected from the group of tumour-induced hypercalcaemia, Paget's disease, osteoporosis, bone metastases, and breast cancer.
PCT/CA2001/001617 2001-05-10 2001-11-15 Liquid injectable formulation of disodium pamidronate WO2002089768A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA2,347,330 2001-05-10
CA002347330A CA2347330C (en) 2001-05-10 2001-05-10 Liquid injectable formulation of disodium pamidronate

Publications (1)

Publication Number Publication Date
WO2002089768A1 true WO2002089768A1 (en) 2002-11-14

Family

ID=4169021

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2001/001617 WO2002089768A1 (en) 2001-05-10 2001-11-15 Liquid injectable formulation of disodium pamidronate

Country Status (3)

Country Link
US (2) US20040147486A1 (en)
CA (2) CA2372450A1 (en)
WO (1) WO2002089768A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005025551A3 (en) * 2003-09-18 2006-01-12 Novartis Ag Pharmaceutical products comprising bisphosphonates

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5243789B2 (en) * 2004-03-15 2013-07-24 シティ・オブ・ホープ Methods and compositions for specific inhibition of gene expression by double stranded RNA
US8071574B2 (en) * 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
WO2006100687A1 (en) * 2005-03-24 2006-09-28 Dabur Pharma Ltd. Disodium pamidronate aqueous formulation
US20070166187A1 (en) * 2006-01-18 2007-07-19 Song Jing F Stabilization of paricalcitol using chlorobutyl or chlorinated butyl stoppers
WO2013171763A1 (en) * 2012-04-27 2013-11-21 Sun Pharmaceutical Industries Ltd Ready to be infused gemcitabine solution

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2141964A1 (en) * 1992-08-27 1994-03-17 Gerhard Winter Pharmaceutical agents containing diphosphonic acids and salts thereof
WO2000034293A1 (en) * 1998-12-10 2000-06-15 Aesgen, Inc. Method for preparation of disodium pamidronate
DE20106394U1 (en) * 2001-04-11 2001-08-09 Helm Pharmaceuticals Gmbh Pharmaceutical preparation

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2405254C2 (en) * 1974-02-04 1982-05-27 Henkel KGaA, 4000 Düsseldorf Use of 3-amino-1-hydroxypropane-1, 1-diphosphonic acid or its water-soluble salts for influencing calcium metabolic disorders in the human or animal body
DE2943498C2 (en) * 1979-10-27 1983-01-27 Henkel KGaA, 4000 Düsseldorf Process for the preparation of 3-amino-1-hydroxypropane-1,1-diphosphonic acid
US4304734A (en) * 1980-10-16 1981-12-08 Vysoka Skola Chemicko-Technologicka 6-Amino-1-hydroxyhexylidene diphosphonic acid, salts and a process for production thereof
US4439194A (en) * 1981-09-08 1984-03-27 Merck & Co., Inc. Water and drug delivery system for suppository use
US4513891A (en) * 1982-04-15 1985-04-30 Sterling Drug Inc. Spray dispensing container and valve therefor
DE3225469A1 (en) * 1982-07-05 1984-01-05 Schering AG, 1000 Berlin und 4709 Bergkamen DIPHOSPHONIC ACID DERIVATIVES AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM
US4797388A (en) * 1984-05-21 1989-01-10 Cetus Corporation Pharmaceutical compositions with galactitol as carrier
DE3428524A1 (en) * 1984-08-02 1986-02-13 Boehringer Mannheim Gmbh, 6800 Mannheim NEW DIPHOSPHONIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
US4639338A (en) * 1984-08-06 1987-01-27 Ciba-Geigy Corporation Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
IT1187828B (en) * 1985-05-24 1987-12-23 Gentili Ist Spa PHARMACEUTICAL COMPOSITION BASED ON DIPHOSPHONATES FOR THE TREATMENT OF ARETROSIS
US4902679A (en) * 1985-12-13 1990-02-20 Norwich Eaton Pharmaceuticals, Inc. Methods of treating diseases with certain geminal diphosphonates
US4816259A (en) * 1987-02-12 1989-03-28 Chase Chemical Company, L.P. Process for coating gelatin capsules
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
US5139786A (en) * 1989-07-07 1992-08-18 Ciba-Geigy Corporation Topical formulations
PH27186A (en) * 1989-09-07 1993-04-16 Ciba Geigy Ag Double-coated granules of disodium pamidronate
NZ236618A (en) * 1990-01-03 1997-06-24 Ciba Geigy Ag Treating and preventing osteoporosis using insulin-like growth factor i (igf i) in conjunction with a bone antiresorptive active compound
US5159108A (en) * 1990-09-18 1992-10-27 Merck & Co., Inc. Process for preparing an antihypercalcemic agent
ATE126059T1 (en) * 1991-10-11 1995-08-15 Squibb & Sons Inc USE OF FARNESYL-PROTEIN TRANSFERASIN HIBITORS FOR THE PRODUCTION OF A MEDICINAL PRODUCT FOR BLOCKING NEOPLASTIC TRANSFORMATION OF CELLS CAUSED BY RAS-ONCOGENES.
JPH07502507A (en) * 1991-12-17 1995-03-16 プロクター、エンド、ギャンブル、ファーマスーティカルズ、インコーポレーテッド Method for treating osteoporosis using bisphosphonates and parathyroid hormone
EP0550385A1 (en) * 1991-12-19 1993-07-07 Ciba-Geigy Ag Oral pharmaceutical compositions containing derivatives of methane-diphosphonic acid and 18-crown-6 ethers
US5756117A (en) * 1992-04-08 1998-05-26 International Medical Asscociates, Inc. Multidose transdermal drug delivery system
TW237386B (en) * 1992-04-15 1995-01-01 Ciba Geigy
DE69324684T2 (en) * 1992-06-30 1999-11-25 Procter & Gamble Pharma MEDICINAL PRODUCTS FOR THE TREATMENT OF ARTHRITIS CONTAINING PHOSPHONATES AND NSAIDS
AU670337B2 (en) * 1992-11-30 1996-07-11 Novartis Ag Use of certain methanebisphosphonic acid derivatives in fracture healing
US5366965A (en) * 1993-01-29 1994-11-22 Boehringer Mannheim Gmbh Regimen for treatment or prophylaxis of osteoporosis
US5403829A (en) * 1993-03-24 1995-04-04 Leiras Oy Use of bisphosphonates in endo-osteal bone surgery
FR2703590B1 (en) * 1993-04-05 1995-06-30 Sanofi Elf USE OF BISPHOSPHONIC ACID DERIVATIVES FOR THE PREPARATION OF MEDICINES FOR PROMOTING BONE REPAIR.
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5591730A (en) * 1993-10-12 1997-01-07 The Regents Of The University Of California Inhibition of urinary calculi growth
EP0730578A4 (en) * 1993-11-24 1997-10-08 Merck & Co Inc Indolyl group containing compounds and the use thereof to promote the release of growth hormone(s)
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
GB9408775D0 (en) * 1994-05-04 1994-06-22 Ciba Geigy Ag Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration
DE4416928C1 (en) * 1994-05-13 1995-08-17 Lohmann Gmbh & Co Kg Medical adhesive material for sweat-resistant dressings etc.
US5449819A (en) * 1994-06-06 1995-09-12 Merck & Co., Inc. Process for removing waste pox, alendronate and its by products
US5780455A (en) * 1994-08-24 1998-07-14 Merck & Co., Inc. Intravenous alendronate formulations
JP3411690B2 (en) * 1994-09-21 2003-06-03 帝人株式会社 Alendronate sodium preparation for topical administration
JP3576608B2 (en) * 1994-11-15 2004-10-13 日東電工株式会社 Patches and patch preparations
US5652227A (en) * 1995-01-30 1997-07-29 Teronen; Olli Pekka Inhibition of the degradation of connective tissue matrix protein components in mammals
MY118354A (en) * 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
JPH11513383A (en) * 1995-09-29 1999-11-16 ノバルティス アクチェンゲゼルシャフト How to treat horse scaphoid disease
US5723151A (en) * 1995-11-06 1998-03-03 Eastman Chemical Company Cellulose acetate phthalate enteric coating compositions
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
US6117856A (en) * 1996-02-14 2000-09-12 Binderman; Itzhak Topical bisphosphonates for prevention of bone resorption
IL120270A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis
US5898038A (en) * 1996-03-19 1999-04-27 Board Of Regents, The University Of Texas System Treatment of osteoporosis and metabolic bone disorders with nitric oxide substrate and/or donors
US20020035058A1 (en) * 1996-05-15 2002-03-21 The University Of Sheffield Isopentenyl pyrophosphate isomerase (IPI) and/or prenyl transferase inhibitors
US5672592A (en) * 1996-06-17 1997-09-30 Guilford Pharmaceuticals Inc. Certain phosphonomethyl-pentanedioic acid derivatives thereof
US5780055A (en) * 1996-09-06 1998-07-14 University Of Maryland, Baltimore Cushioning beads and tablet comprising the same capable of forming a suspension
US6376477B2 (en) * 1996-11-25 2002-04-23 Merck & Co., Inc. Combination of an agent that binds to the androgen receptor and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism
US6080779A (en) * 1996-12-13 2000-06-27 Osteoscreen, Inc. Compositions and methods for stimulating bone growth
UA59384C2 (en) * 1996-12-20 2003-09-15 Пфайзер, Інк. Preventing bone mass loss and recovery thereof by means of prostaglandin agonists
SE9702401D0 (en) * 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
UA53716C2 (en) * 1997-06-25 2003-02-17 Пфайзер Продактс Інк. A substituted dipeptide tartaric salt as an agent stimulating the growth hormone secretion
AU7445498A (en) * 1997-06-25 1999-01-04 Pfizer Inc. Dipeptide derivatives as growth hormone secretagogues
US5994329A (en) * 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6015801A (en) * 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption
US6124314A (en) * 1997-10-10 2000-09-26 Pfizer Inc. Osteoporosis compounds
JP4761093B2 (en) * 1997-12-10 2011-08-31 シクロスポリン セラポイティクス リミテッド Pharmaceutical composition comprising omega-3 fatty acid oil
US6416964B2 (en) * 1998-01-29 2002-07-09 Merck & Co., Inc. Methods of identifying modulators of kinases responsive to stress
EP0950417A3 (en) * 1998-02-23 2000-02-23 Pfizer Products Inc. Treatment of skeletal disorders
US20010025028A1 (en) * 1998-03-13 2001-09-27 Merck & Co., Inc. Methods of inhibiting bone resorption
US6750340B2 (en) * 1998-04-02 2004-06-15 Mbc Research, Inc. Bisphosphonate conjugates and methods of making and using the same
US6214812B1 (en) * 1998-04-02 2001-04-10 Mbc Research, Inc. Bisphosphonate conjugates and methods of making and using the same
US6358951B1 (en) * 1998-08-21 2002-03-19 Pfizer Inc. Growth hormone secretagogues
US5998390A (en) * 1998-09-28 1999-12-07 The Research Foundation Of State University Of New York Combination of bisphosphonate and tetracycline
FR2784031B1 (en) * 1998-10-02 2002-02-01 Sanofi Elf USE OF BISPHOSPHONIC ACID DERIVATIVES FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF LAMPS
US20010006980A1 (en) * 1998-10-15 2001-07-05 Harada Shun-Ichi Methods for stimulating bone formation
US6414006B1 (en) * 1998-10-15 2002-07-02 Merck Frosst Canada & Co. Methods for inhibiting bone resorption
US6194578B1 (en) * 1998-11-20 2001-02-27 Pfizer Inc. Dipeptide derivatives
US6160165A (en) * 1998-12-10 2000-12-12 Aesgen, Inc. Method for preparation of disodium pamidronate
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US20010044427A1 (en) * 1999-12-20 2001-11-22 Sidney Mazel Pharmaceutical kit
US20020002140A1 (en) * 2000-01-14 2002-01-03 Holick Michael F. Novel bisphosphonates and uses thereof
WO2001053297A1 (en) * 2000-01-20 2001-07-26 Merck & Co., Inc. Alpha v integrin receptor antagonists
US6677320B2 (en) * 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance
PE20011065A1 (en) * 2000-02-01 2001-11-21 Procter & Gamble PROCESS FOR MANUFACTURING GEMINAL BISPHOSPHONATES
JP2001253827A (en) * 2000-02-15 2001-09-18 Pfizer Prod Inc Composition and method for treating osteoporosis
WO2001060377A2 (en) * 2000-02-17 2001-08-23 Genzyme Corporation Methods for treatment of lysosomal storage diseases using biphosphonates
AUPR018900A0 (en) * 2000-09-18 2000-10-12 Fh Faulding Pty Limited Pamidronate solution
US20020004218A1 (en) * 2000-03-31 2002-01-10 Rodan Gideon A. Methods for identifying compounds useful for inhibiting geranylgeranyl diphosphate synthase
US6943155B2 (en) * 2000-04-07 2005-09-13 Lenard M. Lichtenberger Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced GI toxicity
US7084126B1 (en) * 2000-05-01 2006-08-01 Healthpartners Research Foundation Methods and compositions for enhancing cellular function through protection of tissue components
US20020028792A1 (en) * 2000-07-06 2002-03-07 American Home Products Corporation Combinations of bisphosphonates, estrogens and estrogenic agents
US20020019373A1 (en) * 2000-07-06 2002-02-14 American Home Products Corporation Combinations of bisphosphonates and estrogenic agents
US6638920B2 (en) * 2000-07-21 2003-10-28 Merck & Co., Inc. Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
DK1326630T3 (en) * 2000-09-18 2008-09-15 Sanos Bioscience As Use of GLP-2 peptides
EE200300477A (en) * 2001-05-02 2003-12-15 Sicor, Inc. Injectable pamidronate disodium

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2141964A1 (en) * 1992-08-27 1994-03-17 Gerhard Winter Pharmaceutical agents containing diphosphonic acids and salts thereof
WO2000034293A1 (en) * 1998-12-10 2000-06-15 Aesgen, Inc. Method for preparation of disodium pamidronate
DE20106394U1 (en) * 2001-04-11 2001-08-09 Helm Pharmaceuticals Gmbh Pharmaceutical preparation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
EZRA A. ET AL: "Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption.", ADVANCED DRUG DELIVERY REVIEWS, (31 AUG 2000) 42/3 (175-195)., XP001056768 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005025551A3 (en) * 2003-09-18 2006-01-12 Novartis Ag Pharmaceutical products comprising bisphosphonates
JP2007505861A (en) * 2003-09-18 2007-03-15 ノバルティス アクチエンゲゼルシャフト Pharmaceutical products containing bisphosphonates
AU2004271731B2 (en) * 2003-09-18 2008-07-24 Novartis Ag Pharmaceutical products comprising bisphosphonates
KR101015718B1 (en) * 2003-09-18 2011-02-22 노파르티스 아게 Pharmaceutical products comprising bisphosphonates
US7932241B2 (en) 2003-09-18 2011-04-26 Novartis Ag Pharmaceutical products comprising bisphosphonates
JP4802096B2 (en) * 2003-09-18 2011-10-26 ノバルティス アーゲー Pharmaceutical products containing bisphosphonates

Also Published As

Publication number Publication date
US20040147486A1 (en) 2004-07-29
US20050182030A1 (en) 2005-08-18
CA2347330C (en) 2002-03-12
CA2347330A1 (en) 2001-09-19
CA2372450A1 (en) 2001-09-19

Similar Documents

Publication Publication Date Title
RU2325913C2 (en) Application of zoledrone acid, its salts, hydrates and method of antinociceptive or antiallodynic treatment of pain, method of neurotic pain treatment
AU693541B2 (en) Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration
ES2524690T3 (en) Long-term sustained release pharmaceutical composition containing an aqueous bisphosphonate suspension
AU2002217061A1 (en) Use of bisphosphonates for pain treatment
HU229054B1 (en) Pharmaceutical parenteral composition containing biphosphonate
ZA200601209B (en) Pharmaceutical products comprising bisphosphonates
US20050182030A1 (en) Liquid injectable formulation of disodium pamidronate
EP0600834A1 (en) Use of methanebisphosphonic acid derivatives for the manufacture of a medicament for fracture healing
AU2001261283B2 (en) Use of Zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases
JP3118258B2 (en) Pharmaceuticals containing diphosphonic acid and its salts
AU670337B2 (en) Use of certain methanebisphosphonic acid derivatives in fracture healing
RU2657833C2 (en) Stabilized dosage form of etidronate-cytarabine conjugate and its application
JP5607408B2 (en) Alendronate-containing injection

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP